Cargando…
S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428410/ http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca |
_version_ | 1785090462393040896 |
---|---|
author | Vachhani, Pankit Perkins, Andrew Mascarenhas, John Al-Ali, Haifa Kathrin Kiladjian, Jean-Jacques Cerquozzi, Sonia Dybko, Jaroslaw Delgado, Regina Garcia Rivas, Jesus Hernández Hebart, Holger Huang, Zhuying Krejsa, Cecile Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Vannucchi, Alessandro |
author_facet | Vachhani, Pankit Perkins, Andrew Mascarenhas, John Al-Ali, Haifa Kathrin Kiladjian, Jean-Jacques Cerquozzi, Sonia Dybko, Jaroslaw Delgado, Regina Garcia Rivas, Jesus Hernández Hebart, Holger Huang, Zhuying Krejsa, Cecile Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Vannucchi, Alessandro |
author_sort | Vachhani, Pankit |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10428410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104284102023-08-17 S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) Vachhani, Pankit Perkins, Andrew Mascarenhas, John Al-Ali, Haifa Kathrin Kiladjian, Jean-Jacques Cerquozzi, Sonia Dybko, Jaroslaw Delgado, Regina Garcia Rivas, Jesus Hernández Hebart, Holger Huang, Zhuying Krejsa, Cecile Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Vannucchi, Alessandro Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428410/ http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Oral Sessions Vachhani, Pankit Perkins, Andrew Mascarenhas, John Al-Ali, Haifa Kathrin Kiladjian, Jean-Jacques Cerquozzi, Sonia Dybko, Jaroslaw Delgado, Regina Garcia Rivas, Jesus Hernández Hebart, Holger Huang, Zhuying Krejsa, Cecile Qamoos, Hope Mcgreivy, Jesse Rothbaum, Wayne P. Verstovsek, Srdan Vannucchi, Alessandro S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title | S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title_full | S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title_fullStr | S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title_full_unstemmed | S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title_short | S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS) |
title_sort | s214: disease-modifying activity of navtemadlin (nvtm) correlated with survival outcomes in janus kinase inhibitor (jaki) relapsed or refractory (r/r) myelofibrosis (mf) patients (pts) |
topic | Oral Sessions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428410/ http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca |
work_keys_str_mv | AT vachhanipankit s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT perkinsandrew s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT mascarenhasjohn s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT alalihaifakathrin s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT kiladjianjeanjacques s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT cerquozzisonia s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT dybkojaroslaw s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT delgadoreginagarcia s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT rivasjesushernandez s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT hebartholger s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT huangzhuying s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT krejsacecile s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT qamooshope s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT mcgreivyjesse s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT rothbaumwaynep s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT verstovseksrdan s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts AT vannucchialessandro s214diseasemodifyingactivityofnavtemadlinnvtmcorrelatedwithsurvivaloutcomesinjanuskinaseinhibitorjakirelapsedorrefractoryrrmyelofibrosismfpatientspts |